HDAC9 and Duchenne muscular dystrophy: We tested in our model a class I selective human HDAC inhibitor (CpK, Figure 7B), a preclinical development candidate that demonstrated proof-of-concept in an mdx mouse model for Duchenne muscular dystrophy and previously profiled in the porcine model [10].